Home > Insider Trading > Filing (0000890465-13-000039)

Filing Details

Accession Number:: 0000890465-13-000039
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-12-30 17:30:57
Reporting Period:: 2013-12-26

Filing Date:: 2013-12-30
Accepted Time:: 2013-12-30 17:30:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
890465	Nps Pharmaceuticals Inc	NPSP	Biological Products, (No Disgnostic Substances) (2836)	870439579

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192128	M Luke Beshar	550 Hills Drive Bedminster NJ 07921	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-12-26	29,250	$5.71	88,430	No	4	M	Direct
Common Stock	Acquisiton	2013-12-26	8,624	$3.34	97,054	No	4	M	Direct
Common Stock	Disposition	2013-12-26	37,874	$30.02	59,180	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2013-12-26	29,250	$0.00	29,250	$5.71
Common Stock	Stock Options	Disposition	2013-12-26	8,624	$0.00	8,624	$3.34

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2019-01-20	No	4	M	Direct
106,376		2020-02-09	No	4	M	Direct

Footnotes

The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 12, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $30.00 and $30.04. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On January 20, 2009, the Reporting Person received a grant of 73,125 performance-based stock options under the Issuer's 1998 Stock Option Plan. Options vest and become exercisable 50% on the second anniversary of the date of grant and 50% on the third anniversary of the grant date. The actual number of options that were determined based on performance of the Issuer's common stock relative to the performance of stock comprising a selected market index was 29,250. As of December 26, 2013 all 29,250 stock options have vested.
On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of December 26, 2013, the performance criteria and the time-based criteria for 64,687 of these options has been satisfied. The options become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.